Clinical trials: Unresectable Locally Advanced Cancer
Pancreatic Neoplasm
Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine For The First Line Treatment of Pancreas Cancer
This is a randomized, multicenter, phase II study of with nab-paclitaxel plus gemcitabine or gemcitabine alone for the treatment of chemotherapy-naïve patients with locally advanced or metastatic pancreatic cancer.
- Trial name
- NCT03807999
- Testing
- Nab-paclitaxel, Gemcitabine
- Volunteers
- 125 people
- Sponsor
- Hacettepe University
Triple-Negative Breast Cancer
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02)
This trial is a registered phase III, randomized, open-label, multicenter study designed to evaluate the efficacy and safety of BL-B01D1 in patients with unresectable locally advanced or metastatic Triple-Negative breast cancer…
- Trial name
- NCT06382142
- Testing
- BL-B01D1, Eribulin, Vinorelbine
- Where
- China
- Volunteers
- 418 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Esophageal Squamous Cell Carcinoma (ESCC)
Induction Chemo-Immunotherapy + Radiotherapy vs Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma
This is a prospective, randomized, phase II clinical study in patients with unresectable stage III-IVA esophageal squamous cell carcinoma (ESCC). Eligible patients will be randomly assigned in a 1:1 ratio to two treatment groups.
- Trial name
- NCT07559045
- Testing
- Paclitaxel plus Cisplatin or Carboplatin (Induction Chemotherapy), Weekly Paclitaxel plus Cisplatin or Carboplatin (Concurrent Chemotherapy)
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Second Affiliated Hospital of Zunyi Medical University
Pancreatic Ductal Adenocarcinoma (PDAC), Unresectable Locally Advanced
Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
This example study evaluates the safety, tolerability, and preliminary anti-tumor activity of investigational, dual-targeting chimeric antigen receptor natural killer (CAR-NK) cell products for patients with advanced pancreatic…
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC), Unresectable Locally Advanced, Metastatic Disease
- Trial name
- DUAL-NK-PDAC (NCT07627711)
- Testing
- EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1), EB-DNK102 dual-targeting CAR-NK cells (CLDN18.2 + MUC1), Lymphodepleting chemotherapy (Flu/Cy)
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Beijing Biotech
Locally Advanced Unresectable Pancreatic Adenocarcinoma
STR + Anti PD-1 Therapy in Patients with Locally Advanced Unresectable Pancreatic Adenocarcinoma
Stereotactic Radiotherapy + Anti PD-1 Therapy in Patients With Locally Advanced Unresectable Pancreatic Adenocarcinoma
- Trial name
- CA209-9KH (NCT04098432)
- Testing
- Nivolumab, Stereotactic radiotherapy
- Where
- 4 sites in Czechia
- Volunteers
- 15 people
- Sponsor
- University Hospital Hradec Kralove
Locally Advanced Digestive System Neuroendocrine Carcinoma, Locally Advanced Pancreatic Neuroendocrine Carcinoma
Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin
This phase II trial studies how well liposomal irinotecan, leucovorin, and fluorouracil work in treating patients with high grade neuroendocrine cancer of gastrointestinal, unknown, or pancreatic origin that does not respond to…
- Conditions
- Locally Advanced Digestive System Neuroendocrine Carcinoma, Locally Advanced Pancreatic Neuroendocrine Carcinoma, Metastatic Digestive System Neuroendocrine Carcinoma, Metastatic Pancreatic Neuroendocrine Carcinoma
- Trial name
- NCT03736720
- Testing
- Fluorouracil, Leucovorin, Liposomal Irinotecan
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Roswell Park Cancer Institute
Unresectable Locally Advanced or Metastatic, Medullary Thyroid Carcinoma
Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma
Open-label Study to Evaluate the Safety and Tolerability of Vandetanib 300 mg/day in Japanese Patients with Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma.
- Trial name
- NCT01661179
- Testing
- Vandetanib 300mg
- Where
- 4 sites in Japan
- Volunteers
- 14 people
- Sponsor
- Genzyme, a Sanofi Company
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma
A randomized, Double-blind, Multicenter, phase III Clinical Study of Comparing the Efficacy and Safety of AK104 Plus Oxaliplatin and Capecitabine (XELOX) Versus Placebo Plus XELOX as First-line Treatment for locally advanced…
- Trial name
- NCT05008783
- Testing
- AK104
- Where
- 7 sites in China
- Volunteers
- 610 people
- Sponsor
- Akeso
Pancreatic Adenocarcinoma Non-resectable
A Study of Vaccination With Poly-ICLC and Dendritic Cells in Patients With Pancreatic Adenocarcinoma
The main purpose of this study is to examine the safety of the study drug in patients with locally advanced unresectable pancreatic adenocarcinoma.
- Trial name
- NCT01677962
- Testing
- Poly-ICLC, dendritic cell
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Medical University of South Carolina
Non-Small Cell Lung Cancer
A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
A Global Study to Assess the Effects of MEDI4736 following concurrent chemoradiation in Patients with Stage III Unresectable Non-Small Cell Lung Cancer.
- Trial name
- PACIFIC (NCT02125461)
- Testing
- MEDI4736
- Where
- 236 sites in United States, Australia and 24 more
- Volunteers
- 713 people
- Sponsor
- AstraZeneca
Pancreatic Cancer Non-resectable
Safety and Performance of a Novel Infusion Catheter System for Peri/Intratumoral Gemcitabine Delivery in Patients With Pancreatic Cancer
This study is testing a new way to deliver the chemotherapy drug Gemcitabine in pancreatic tumors using the catheter Extroducer® Infusion Catheter System.
- Trial name
- NCT07575191
- Testing
- Gemcitabine, Extroducer Infusion Catheter System
- Where
- Sweden
- Volunteers
- 9 people
- Sponsor
- Smartwise Sweden AB
Triple-Negative Breast Cancer
A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Combined With Nab-paclitaxel and Famitinib, of TNBC.
The study is being conducted to evaluate the Opportune Administration of Nab-paclitaxel in the First Line Treatment Strategy, Camrelizumab and Famitinib with/without Nab-paclitaxel, of Patients with Unresectable Locally Advanced…
- Trial name
- NCT05670925
- Testing
- Camrelizumab plus Famitinib with/without nab-Palitaxel
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Fudan University
Locally Advanced Unresectable Gastric Cancer
A Single Arm, Phase II Exploratory Clinical Study of Pemitinib in Advanced Gastric Cancer With Previous Standard Therapy Failure the FGFR Variant
purpose of research： fundamental purpose: To evaluate the effectiveness of pemitinib in patients with advanced gastric cancer who have failed standard therapy with fibroblast growth factor receptor 1-3 (FGFR1-3) variant…
- Trial name
- NCT05997459
- Testing
- Pemigatinib
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Sun Yat-sen University
Pancreatic Ductal Adenocarcinoma (PDAC)
A Study of CEND-1 With Chemotherapy as First-Line Therapy in Patients With Pancreatic Ductal Adenocarcinoma
The purpose of this study is to evaluate the efficacy and safety of CEND-1 in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel and placebo as first-line treatment in patients with Locally Advanced…
- Trial name
- NCT06261359
- Testing
- CEND-1, Gemcitabine, Nab paclitaxel
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Pancreatic Adenocarcinoma
Portal Vein Thrombosis Associated With Unresectable Pancreatic Cancers : a Prospective Multicentric Cohort Study
Little is known concerning the management of portal vein thrombosis (PVT) in digestive cancers other than hepato-cellular carcinoma (HCC).
- Trial name
- THROMPAN (NCT04814251)
- Testing
- Observationnal cohort
- Volunteers
- 200 people
- Sponsor
- Poitiers University Hospital
Carcinoma, Squamous Cell, Anorectal Cancer
Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment
The purpose of this study is to gather information on the safety and effectiveness of lenvatinib combined with pembrolizumab in anal/rectal cancer that has spread to other parts of the body and will not respond to standard care.
- Trial name
- NCT06669572
- Testing
- Pembrolizumab, Lenvatinib
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Chicago
Non-small Cell Lung Cancer
TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy
The purpose of this study is to compare the anti-tumor efficacy of oral single-agent rociletinib, as measured by investigator assessment of the PFS, with that of single-agent cytotoxic chemotherapy in patients with EGFR-mutated…
- Trial name
- NCT02322281
- Testing
- Rociletinib, Pemetrexed or gemcitabine or paclitaxel or docetaxel
- Where
- 80 sites in United States, Australia and 8 more
- Volunteers
- 149 people
- Sponsor
- Clovis Oncology, Inc.
Gastric or Gastroesophageal Junction Adenocarcinoma
Retrospective Study of Ramucirumab and Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma
This is a retrospective, multicenter, non-interventional study for the evaluation of real-world efficacy and safety of ramucirumab plus paclitaxel in gastric or gastroesophageal junction adenocarcinoma as part of the…
- Trial name
- NCT04192734
- Where
- 57 sites in South Korea
- Volunteers
- 1,063 people
- Sponsor
- Hallym University Medical Center
Locally Advanced or Metastatic Malignant Solid Tumors
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Specific proteins found in tumors help the tumors spread and grow. People with solid tumors often have a protein called TROP2 in their tumor.
- Trial name
- NCT07287995
- Testing
- ASP2998, Pembrolizumab, Enfortumab Vedotin
- Where
- 9 sites in United States, Japan
- Volunteers
- 428 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Solid Tumours
A Study of AP601 in Patients With Locally Unresectable Advanced or Metastatic Solid Tumors
A Phase 1, Open-Label Study of the Safety, Tolerability,Pharmacokinetics, Pharmacodynamics and Clinical Activity of AP601 in Patients with Solid Tumours.The study is designed to find the highest dose of AP601 that can be given…
- Trial name
- NCT07165067
- Testing
- AP601
- Where
- 3 sites in Australia
- Volunteers
- 36 people
- Sponsor
- AP Biosciences Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.